SecBot SecBot
PRESS-RELEASE ·Filed May 19, 2026

ARTV

Artiva Biotherapeutics, Inc.
BULLISH
Impact 8/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The EULAR data are the primary catalyst. If the late-breaking oral confirms the 71% ACR50 with deep B-cell depletion comparable to CAR T, the thesis of an 'off-the-shelf' alternative to CAR T in autoimmune indications strengthens materially. Monitor the webcast on June 8 and feedback from key opinion leaders. The Phase 3 initiation in 2026 is a major milestone derisking event, if the data are consistent, expect upward re-rating. Risk: interim small-sample data (31 patients) may not replicate in pivotal trials; competitive landscape with other NK and CAR T autoimmune programs.

DirectionBullish
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$7.84
T+0 close · May 19, 2026 · via day close
Latest settled
+25.26%
T+20 · $9.82
Vs SPY
+24.51%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 20 $7.84entry
  2. T+1 · 6mo ago +1.91%α +1.72% · $7.99
  3. T+5 · 6mo ago −2.68%α −3.92% · $7.63
  4. T+20 · 5mo ago +25.26%α +24.51% · $9.82
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics announced five data presentations at the EULAR 2026 Congress (June 3-6, 2026) for its AlloNK (AB-101) allogeneic NK cell therapy in autoimmune diseases. A late-breaking oral abstract showed 71% ACR50 response in refractory RA patients with ≥6-month follow-up, no relapses, and B-cell depletion comparable to autologous CD19 CAR T therapy. The company plans a Phase 3 registrational trial in refractory RA in 2026. This is a significant clinical data catalyst for a clinical-stage biotech, the data are early and interim but the CAR T comparability claim and refractory RA response rates are the key bullish signals.

Key Facts

  • Five abstracts accepted at EULAR 2026, including one late-breaking oral presentation.
  • Late-breaking abstract (LB0003): 71% ACR50 response in refractory RA patients with ≥6-month follow-up; zero relapses or new immunomodulatory agents required.
  • First patient with severe Sjögren disease treated with AlloNK + rituximab showed positive experience (abstract OP0129).
  • Data claim B-cell depletion comparable to autologous CD19 CAR T therapies (abstracts POS0355, AB0345).
  • AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy.
  • Company plans to initiate a Phase 3 registrational trial in refractory RA in 2026.
  • Live post-meeting webcast with KOL Dr. Paul Emery scheduled for June 8, 2026 at 8:15 am EDT.
  • Market cap ~$228M, 92% analyst buy rating, $100M insider purchases in last 30 days.

Financial Impact

No financial data provided in press release. Artiva is pre-revenue clinical-stage (no revenue, no EPS). Market cap ~$228M. Insider purchases totalling $100M in 30 days signal strong confidence. If AlloNK progresses to approval in refractory RA (large market opportunity, RA biologics market >$25B globally), the value inflection is substantial.

Risk Factors

  • Interim clinical data from 31 patients across trials, small sample, not randomized; results may not replicate in Phase 3.
  • AlloNK is unapproved; regulatory path uncertain; safety/efficacy risks in larger populations.
  • Competition from multiple CAR T and NK cell therapies in autoimmune indications (Kyverna, BMS, Fate, etc.).
  • Cash runway not disclosed; dilutive financing possible as a clinical-stage company without revenue.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3297953

Track record

33 reports on ARTV

Performance horizon

10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026